By performing whole exome sequencing (WES) on paired tumor tissues from 23 patients with GC before trastuzumab treatment at baseline and at progressive disease (PD), Xu et al. identified the most common genes mutations (AURKA, MYC, STK11, and LRP6) associated with failure of anti-HER2 therapy [108]. This evidence concerns the gene STK11 and neoplasm.